Search

Your search keyword '"Colantuoni, G"' showing total 43 results

Search Constraints

Start Over You searched for: Author "Colantuoni, G" Remove constraint Author: "Colantuoni, G" Database MEDLINE Remove constraint Database: MEDLINE
43 results on '"Colantuoni, G"'

Search Results

1. Efficacy of adjuvant chemotherapy schedules for breast cancer according to body mass index: results from the phase III GIM2 trial.

2. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial.

3. Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer.

4. Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting.

5. The optional approach of oncogene-addicted non-small cell lung cancer with brain metastases in the new generation targeted therapies era.

6. Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy) focused on activity, efficacy and safety.

7. Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial.

8. Weekly docetaxel versus CMF as adjuvant chemotherapy for older women with early breast cancer: final results of the randomized phase III ELDA trial.

9. Is primary surgery for locally advanced/metastatic breast cancer a better choice than chemotherapic treatment?

10. Bone effect of adjuvant tamoxifen, letrozole or letrozole plus zoledronic acid in early-stage breast cancer: the randomized phase 3 HOBOE study.

11. Targeting angiogenesis for treatment of NSCLC brain metastases.

12. The role of antiangiogenetic agents in the treatment of breast cancer.

13. Management of unfit older patients with advanced NSCLC.

14. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer.

15. Recent developments of targeted therapies in the treatment of non-small cell lung cancer.

16. New avenues for second-line treatment of metastatic non-small-cell lung cancer.

17. Granulocyte-macrophage colony stimulating factor is anabolic and interleukin-1beta is catabolic for rat articular chondrocytes.

18. New insights in drug development for the non-small cell lung cancer therapy.

19. Erlotinib in non-small-cell lung cancer.

20. Three cases of long-lasting tumor control with erlotinib after progression with gefitinib in advanced non-small cell lung cancer.

21. Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer.

22. Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer.

23. Chemotherapy of advanced NSCLC in special patient population.

24. Screening for lung cancer: New horizons?

25. Do arachidonic acid and its metabolites, secreted by rheumatoid and osteoarthritic synovial tissue, account for the strong inhibition of DNA synthesis in cultured human articular chondrocytes? A novel approach to the mechanism of tissue damage.

26. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study.

27. Treatment of small cell lung cancer in the elderly.

28. Italian clinical research in non-small-cell lung cancer.

29. Chemotherapy of breast cancer in the elderly.

30. The role of new targeted therapies in small-cell lung cancer.

31. Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.

32. Complete response of severe symptomatic bone marrow metastases from heavily pretreated breast cancer with a 3-weekly trastuzumab schedule. A clinical case.

33. Method for selecting populations of rat articular chondrocytes that exhibit distinct growth and metabolic characteristics, and their responses to growth factors, PMA and vitamin D3.

34. Supportive care in patients with advanced non-small-cell lung cancer.

35. Single agent vinorelbine as first-line chemotherapy in elderly patients with advanced breast cancer.

36. Human synovium produces substances that inhibit DNA and stimulate proteoglycan and collagen synthesis by cultured human articular chondrocytes and synovial fibroblasts.

37. Chemotherapy of non-small cell lung cancer in elderly patients.

38. Oral cytotoxic drugs.

39. Chemotherapy of advanced NSCLC in the elderly.

40. Granulocyte-macrophage colony stimulating factor activates proteoglycan, type II collagen, and cAMP production by rat articular chondrocytes through specific binding sites.

41. Weekly low dose epirubicin in elderly cancer patients.

43. Cis-platin-Mecy as salvage chemotherapy in recurrent advanced ovarian carcinoma.

Catalog

Books, media, physical & digital resources